Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
120Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $344.23M | $-24.16M | $-0.83 |
| 2024 | $332.07M | $18.25M | $0.66 |
| 2023 | $219.79M | $-57.47M | $-2.14 |
| 2022 | $137.04M | $-67.14M | $-2.58 |
| 2021 | $94.08M | $-31.29M | $-1.24 |
Social Signal Score
Earnings
Mon, Nov 2(in 3 months)
Consensus estimate $-0.38 per share
Typical surprise +82.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$-0.07 vs $-0.41beat
- Wed, May 6$-0.49 vs $-0.49beat
- Thu, Feb 26$-0.08 vs $-0.23beat
- Mon, Nov 3$-0.02 vs $-0.34beat
- Mon, Aug 4$0.15 vs $-0.51beat
- Mon, May 5$-0.20 vs $-0.08miss
Estimates and results for CSTL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
CSTLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsmarketbeat.com·2d ago·Positive
Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction Castle Biosciences NASDAQ: CSTL reported continued momentum in its core diagnostic franchises during the second quarter, prompting the company to raise its outlook by more than the amount of its reported beat, according to CFO Frank Stokes.
View source ↗